News
HOLX
75.10
+0.24%
0.18
Agree To Purchase Hologic At $55, Earn 1.6% Annualized Using Options
NASDAQ · 9h ago
ClearBridge Appreciation ESG Strategy Q1 2024 Portfolio Manager Commentary
Soft landing rally that took hold in November 2023 continued in 2024's first quarter. Every sector, except for real estate, posted positive absolute returns. The S&P 500's 10.56% quarterly advance was the 11th best start to a year since 1950. ClearBridge is watching sustainability-related opportunities presented by artificial intelligence.
Seeking Alpha · 13h ago
Hologic (HOLX) to Report Q2 Earnings: What's in the Cards?
NASDAQ · 1d ago
Add Up The Parts: SUSA Could Be Worth $116
NASDAQ · 1d ago
ClearBridge Sustainability Leaders Strategy Q1 2024 Portfolio Manager Commentary
U.S. Equities continued their upward march in the first quarter as the momentum rally showed few signs of flagging. ClearBridge was active in seizing opportunities as a concentrated market left pockets where excellent assets were undervalued. The Strategy delivered strong absolute performance driven by industrials and consumer discretionary holdings.
Seeking Alpha · 1d ago
U.S. RESEARCH ROUNDUP-3M, J&J, Nuvalent
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. 3M, J&J and Nuvalent are among the companies. Analysts also raise their targets on Amazon, Tractor Supply, UnitedHealth Group and Amgen. NEW: 3M cuts its target price to $110 from $118; 10X Genomics cuts target price.
Reuters · 1d ago
Weekly Report: what happened at HOLX last week (0408-0412)?
Weekly Report · 3d ago
Hologic's (HOLX) New Launches Aid, Macroeconomic Issues Ail
NASDAQ · 6d ago
BAYER AND HOLOGIC COLLABORATING TO DELIVER CONTRAST-ENHANCED MAMMOGRAPHY
Reuters · 04/11 18:08
Hologic: A Strong Buy Amidst Growth, Innovation, and Favorable Market Dynamics
TipRanks · 04/10 09:35
Analysts Conflicted on These Healthcare Names: Tilray (TLRY), Hologic (HOLX) and Bicycle Therapeutics (BCYC)
TipRanks · 04/10 09:32
Hologic Price Target Maintained With a $90.00/Share by Needham
Dow Jones · 04/10 09:29
Needham Reiterates Buy on Hologic, Maintains $90 Price Target
Benzinga · 04/10 09:21
RBC Capital Sticks to Its Hold Rating for Hologic (HOLX)
McNamara covers the Healthcare sector, focusing on stocks such as QuidelOrtho and Bio-Rad Laboratories. The company’s shares closed yesterday at $77.38. The analyst consensus on Hologic is a Moderate Buy with an average price target of $85.33.
TipRanks · 04/09 01:45
Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It
NASDAQ · 04/08 13:00
Weekly Report: what happened at HOLX last week (0401-0405)?
Weekly Report · 04/08 09:20
U.S. RESEARCH ROUNDUP-Conocophillips, Fastly, Vital Energy
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Broadcom, Fastly, Vital Energy, Conocophillips, 3M among companies with revised targets. Broad com resumes coverage with buy rating; Deutsche Bank resumes coverage.
Reuters · 04/08 07:13
HOLOGIC INC <HOLX.O>: RBC RAISES TARGET PRICE TO $81 FROM $76
Reuters · 04/08 06:27
Calculating The Intrinsic Value Of Hologic, Inc. (NASDAQ:HOLX)
Using the 2 Stage Free Cash Flow to Equity, Hologic fair value estimate is US$93.88 Current share price of US$77.28 suggests Hologic is potentially trading close to its fair value. Hologic's fair value is 12% higher than its analyst price target. We use the Discounted Cash Flow model to estimate the attractiveness of Hologic, Inc. (NASDAQ:HOLX)
Simply Wall St · 04/05 12:28
Hologic Is Maintained at In-Line by Evercore ISI Group
Dow Jones · 04/04 16:54
More
Webull provides a variety of real-time HOLX stock news. You can receive the latest news about Hologic Inc through multiple platforms. This information may help you make smarter investment decisions.
About HOLX
Hologic, Inc. is a medical technology company primarily focused on improving women's health and well-being through early detection and treatment. The Company is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products. It operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The Diagnostics segment offers a wide range of diagnostic products, which are used primarily to aid in the screening and diagnosis of human diseases. The Breast Health segment offers a broad portfolio of solutions for breast cancer care primarily in the areas of radiology, breast surgery, pathology and treatment. The GYN Surgical segment products include MyoSure hysteroscopic tissue removal system, NovaSure endometrial ablation system, Fluent fluid management system and Acessa ProVu laparoscopic radiofrequency ablation system. The Skeletal Health segment products include Horizon DXA Systems and Fluoroscan Insight FD.